TRACON Pharmaceuticals (TCON)
(Delayed Data from OTC)
$0.19 USD
+0.06 (47.06%)
Updated Sep 18, 2024 03:52 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 21 - 40 ( 72 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ENVASARC Trial Doses 36th Patient, Triggering Initial IDMC Efficacy Review to Proceed
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Time Limit Extended Until September 30, 2022, For Final Decision in Ongoing Arbitration
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Two Interim Safety Reviews and Interim Efficacy Data Expected for Pivotal ENVASARC Trial in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ENVASARC Amended Protocol Approved and Open at All 30 Clinical Sites
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Envafolimab Interim Efficacy Data at Newly Doubled Dose Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NCI-Sponsored Phase 2 Trial of TRC102 in Lung Cancer Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
IDMC Recommends ENVASARC Trial Continues With Higher Dosing
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; All Eyes on Next ENVASARC Interim Data Review Before YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partnership With Eucure Biopharma Announced for Development of YH001 in Oncology Indications in North America
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Pivotal Envafolimab Trial Data Still Expected 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ENVASARC Pivotal Trial to Continue as Planned After Second IDMC Review of Safety Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Independent Data Monitoring Committee Recommends Proceeding With ENVASARC Pivotal Trial Following Safety Data Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; IDMC Review of Pivotal Envafolimab Trial in 2Q21, and Interim Efficacy Data Expected in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results; Interim Data From the ENVASARC Trial in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in the ENVASARC Registration Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Interim Pivotal ENVASARC Trial Efficacy and Safety Data Expected Mid-2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants TRC102 Orphan Drug Designation for Malignant Glioma, Including Glioblastoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E